Blog
RSS FeedPosted by Michael Wonder on 18 Nov 2020
Dupixent (dupilumab injection) now approved by Health Canada for patients with severe asthma
17 November 2020 - Only biologic approved in Canada to treat severe asthma with type 2 / eosinophilic phenotype, or oral ...
Posted by Michael Wonder on 13 Nov 2020
Health Canada extends approval of Imvamune to immunisation against monkeypox and orthopox viruses
12 November 2020 - Bavarian Nordic announced today that Health Canada has expanded the approval of the Company’s non-replicating smallpox ...
Posted by Michael Wonder on 12 Nov 2020
Promising new therapy for COVID-19 cleared by U.S., still under review by Health Canada
12 November 2020 - Antibody treatment co-developed by Canadian scientists has been approved by US FDA. ...
Posted by Michael Wonder on 12 Nov 2020
Cystic Fibrosis Canada says 'life-changing' drug coming to Canada, but approval months away
11 November 2020 - The drug's manufacturer says it's moving forward with its cystic fibrosis medicines in Canada. ...
Posted by Michael Wonder on 10 Nov 2020
Manufacturer moves to bring 'life-changing' cystic fibrosis drugs to Canada
10 November 2020 - A pharmaceutical company says it's taking steps to bring cystic fibrosis drugs to Canada in a ...
Posted by Michael Wonder on 10 Nov 2020
Health Canada approves Maviret 8 week treatment duration for treatment naïve patients with genotype 3 compensated cirrhosis
10 November 2020 - Maviret (glecaprevir/pibrentasvir) is the only 8 week oral treatment approved for all hepatitis C virus genotypes. ...
Posted by Michael Wonder on 04 Nov 2020
Health Canada approves Canada’s first HIV self test
3 November 2020 - For the first time, Canadians will have access to at-home HIV self test kits. bioLytical Laboratories ...
Posted by Michael Wonder on 02 Nov 2020
Novartis' MONALEESA-7 Kisqali (ribociclib succinate) study demonstrated statistically significant improvement in overall survival in pre- and peri-menopausal women with HR+/HER2- advanced breast cancer
2 November 2020 - Novartis Pharmaceuticals Canada is pleased to announce that statistically significant overall survival results for Kisqali (ribociclib succinate) ...
Posted by Michael Wonder on 28 Oct 2020
Leo Pharma is withdrawing the drug Picato (ingenol mebutate), used to treat skin lesions, due to the potential increased risk of skin cancer
27 October 2020 - At Health Canada's request, Leo Pharma is withdrawing Picato from the Canadian market. ...
Posted by Michael Wonder on 28 Oct 2020
KYE Pharmaceuticals announces commercial availability of Firdapse in Canada
28 October 2020 - KYE Pharmaceuticals today announced an important milestone, Firdapse (amifampridine phosphate), the first amifampridine product approved in Canada, ...
Posted by Michael Wonder on 27 Oct 2020
Incyte announces Health Canada acceptance of the new drug submission for pemigatinib as a treatment for patients with cholangiocarcinoma
26 October 2020 - Incyte today announced that Health Canada has accepted its new drug submission for pemigatinib, a selective fibroblast ...
Posted by Michael Wonder on 24 Oct 2020
Medicago signs agreements with the Government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine
23 October 2020 - Canadian government to provide $173M in funding for vaccine research and development, and domestic manufacturing capacity. ...
Posted by Michael Wonder on 20 Oct 2020
Health Canada has approved Taltz (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis
19 October 2020 - Taltz is now approved to treat patients across the axSpA spectrum, including ankylosing spondylitis and non-radiographic axSpA. ...
Posted by Michael Wonder on 17 Oct 2020
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma
15 October 2020 - Approval Based on Significant Overall Survival Findings from Phase 3 KEYNOTE-048 Trial. ...
Posted by Michael Wonder on 15 Oct 2020
Health Canada approves first-ever gene replacement therapy, Luxturna
15 October 2020 - Luxturna (voretigene neparvovec), is the first approved therapy for previously untreatable inherited retinal disease. ...